Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benefit-Risk Frameworks May Be Coming To US FDA Advisory Committees

Executive Summary

Structured assessments, which are currently publicly available only for approved products, could help frame questions for panel discussion of specific drugs under review; FDA also exploring ways to make completed frameworks more readily accessible.

Advertisement

Related Content

US FDA Wants Authority To Mandate Minor Post-Approval Quality Changes
Sponsor-FDA Communications In IND Phase Will Get Outside Review
Patient Experience Data: Industry Seeks US FDA Clarity On Submission Pathway And Labeling
US FDA's Benefit/Risk Framework Gets High Marks But Could Be Improved
FDA Can’t Find Efficacy For BioMarin’s Drisapersen

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel